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Summary
Background Gastric cancer is the fourth most common 
cancer worldwide. Surgery in combination with multi-
modal therapy provides the only curative therapy until 
now. The importance of targeted therapy became clear 
over the last few years. Due to the implication of HER2 
and angiogenesis-directed targeted therapies major 
advances in the treatment of gastric cancer could be 
reached. Nevertheless, benefits in survival remain unsat-
isfactory and the development of resistance to monoclo-
nal antibodies is arising.
Methods A comprehensive and comparative litera-
ture research was performed to evaluate the status of 
HER2 and angiogenesis-directed targeted therapy in gas-
tric cancer.
Results Up to now, trastuzumab and ramucirumab 
are the only agents showing remarkable benefits in the 
therapy for the patients suffering from gastric cancer. 
The limitations of targeted therapies in gastric cancer are 
mainly associated with the development of secondary 
resistance.
Conclusion Addition of targeted therapy in second-
line treatment is beneficial when compared with che-
motherapy alone. Nevertheless, results in first-line treat-
ment remain modest. Therefore, new therapeutic agents 
and combinations in the first-line treatment of gastric 
cancer are urgently needed and remain to be validated 
in clinical trials.
Keywords Gastric cancer  · HER2  · Angiogenesis  · Tar-
geted therapy  · Trastuzumab  · Ramucirumab  · Chemo-
resistance
Introduction
Gastric cancer is one of the most commonly diagnosed 
cancers worldwide. Around 700,000 people die due to 
gastric cancer every year. This makes gastric cancer the 
second most common cause of cancer related death in 
the world [1]. Western countries report a lower incidence 
of gastric cancer, patients, however, have a higher mor-
tality due to advanced stages of disease at the time of 
diagnosis [2].
Until now, the only curative therapy option is a mul-
timodal approach in resectable gastric cancer [3, 4]. In 
metastatic disease 5-year survival rate is very poor with a 
median overall survival (OS)below 12 month [5].
The human epidermal growth factor receptor 2 
(HER2) is one of the most important targets for targeted, 
anti-cancer therapies. Overexpression and amplification 
of HER2 in gastric cancer leads to a poor prognosis, due 
to the initiation of progression and metastasis [1, 6, 7]. 
A significant benefit in advanced gastric cancer could be 
observed, using the monoclonal antibody trastuzumab, 
in combination with chemotherapy [8].
Due to angiogenesis, networks are built up, supplying 
the tumor with nutrients and oxygen regulated via acti-
vator and inhibitor molecules [9–11]. In angiogenesis, 
the vascular endothelial growth factor (VEGF) family and 
its receptors (VEGFRs) are of substantial importance. In 
mammals, the VEGF family members (ligands) are VEGF-
A, VEGF-B, VEGF-C, VEGF-D, and placenta growth factor 
(PGF). The most important signal transducer is VEGFR-2. 
Through a number of different pathways, VEGFR-2 regu-
lates cell proliferation.
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The increasing attention in tumor vascularization 
leads to the development of antiangiogenic therapies. As 
a result, various humanized antibodies, such as bevaci-
zumab and tyrosine kinase inhibitors (TKIs), have been 
approved for anti-cancer therapies. This article describes 
the actual state of the art therapeutic options in gastric 
cancer. Further, the potential role of new agents in tar-
geted therapy of gastric cancer will be evaluated and 
discussed.
Material and methods
An analytical and comparative PubMed research for tar-
geted therapy in gastric cancer was executed. Results 
were implemented into a critical analysis and discussion 
of the state of the art-targeted therapy of gastric cancer.
Results
Resectable gastric cancer
Up to date, a multimodal approach, consisting of a com-
bination of surgical resection plus/minus chemo (radio) 
therapy remains the only potentially curative option in 
resectable gastric cancer. Chemo (radio) therapy com-
bined with the classical “D2 resection” represents a 
standard procedure in localized gastric cancer. Extend-
ing lymphadenectomy with paraaortic nodal dissection 
brought no significant benefits concerning survival and/
or recurrence [4, 12, 13].
Adjuvant chemotherapy and chemoradiatio
Before the Japanese ACTS-GC trial was investigated, in 
more than 30 randomized trials, comparing adjuvant sys-
temic chemotherapy versus surgery alone in resectable 
cancer, no benefit in patients’ survival could be observed 
[14–16]. Only the ACTS-GC trial with 1059 patients with 
stage II or III gastric cancer (oral S-1 versus D2 gastrec-
tomy alone) demonstrated significant improvement in 
OS [17]. Due to this results could not be found in non-
Japanese patients, S-1 is approved in Japan for adjuvant 
therapy in gastric cancer and in Europe for the treat-
ment of advanced gastric cancer. The results of the Inter-
group-0116 trial established adjuvant chemoradiotherapy 
as a standard treatment for patients suffering from resect-
able gastric cancer. Due to the Intergroup-0116 trial was 
criticized because of inadequate surgical procedures 
the Korean ARTIST trial, which randomly assigned only 
patients who underwent D2 lymphadenectomy, reas-
sessed adjuvant radiotherapy in gastric cancer [3, 13]. 
Unfortunately, no significant benefit in Disease Free Sur-
vival (DFS) and OS could be observed for the entire study 
population [18]. Therefore, further investigations and tri-
als, such as the ARTIST-II trial, the CLASSIC trial or the 
CRITICS trial are needed to find new, beneficial adjuvant 
therapeutic regiments ([17, 19, 20] Table 1).
Neoadjuvant and perioperative chemotherapy
One of the most influential trials investigating periop-
erative chemotherapy in gastric cancer is the Medical 
Research Council Adjuvant Gastric Infusional Chemo-
therapy (MAGIC) trial. The MAGIC trial recruited 503 
patients (74 % potentially resectable gastric cancer, 11 % 
distal esophageal cancer, or 15 % esophago-gastric junc-
tion adenocarcinomas) randomized to three cycles of 
chemotherapy (5-FU, cisplatin and epirubicin) before 
and after radical resection, compared with treatment 
with surgery alone. In the chemotherapy arm, a signifi-
cantly better OS and progression-free survival (PFS) were 
reported. Beside these results, a higher rate of curative 
Table 1 Adjuvant chemotherapy for resectable gastric cancer—A summary of major studies. ([3, 17, 19, 21, 22])
Source, year Adjuvant Chemotherapy UICC Stage 5-yrs OS (95 % CI) treated 5-yrs OS (95 % CI) control HR for OS (95 % CI)
Nitti, D., et al, 2006 [22] Fluorouracil IB–IV 52 % (42–62%) 51% (41–61%) 0.89 (0.51–1.31)
Doxorubicin
Methotrexat + Leucovorin
Fluorouracil IB–IV 33% (23–42%) 36% (26–45%) 1.05 (0.69–1.41)
Epirubicin
Methotrexat + Leucovorin
Sasako, M., et al, 2011 [18] S1 II–III 72 % (68–76%) 61 (57–65%) 0.67 (0.54–0.83)
3-yrs OS (95 % CI) treated 3-yrs OS (95% CI) control HR for OS (95% CI)
Macdonald, JS., et al, 2001 [4] Fluorouracil n.g. 50% (n.a.) 41% (n.a.) 1.35 (1.09–1.66)
Leucovorin
Radiation
Sakuramoto, S., et al, 2007 [23] S1 II–IIIB 80% (76–84%) 70% (66–75%) 0.68 (0.52–0.87)
Bang, YJ., et al, 2012 [20] Capecitabine II–IIIB 83% (79–87%) 78% (74–83%) 0.72 (0.52–1.00)
Oxaliplatin
UICC Union internationale contre le cancer, yrs Years, OS Overall survival, CI Confidence interval, HR Hazard ratio, n.g. not given
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ventional cytotoxic chemotherapy in patients with HER2 
positive advanced gastric cancer was investigated in the 
Trastuzumab for Gastric Cancer (ToGA) trial [8]. In terms 
of tumor response, the ToGA trial showed a clinical bene-
fit in the chemotherapy plus trastuzumab group. Patients 
receiving chemotherapy and trastuzumab had a signifi-
cantly better OS. In a reassessment of HER2 expression 
levels, IHC +++ patients showed the greatest benefit from 
additional trastuzumab [8]. As a result of this reassess-
ment, the European Medicine Agency (EMA) restricted 
approval of trastuzumab to patients suffering from IHC 
+++ or ++/FISH + metastatic gastric or gastro-esopha-
geal junction adenocarcinoma. The National Institute 
for Clinical Excellence limited its recommendation for 
trastuzumab to patients showing IHC +++ disease only in 
the United Kingdom based on this reassessment. Beside 
these restrictions in Europe, in the United States, the 
Food and Drug Administration (FDA) has ratified trastu-
zumab therapy for patients with HER2 overexpression 
without any further specification.
To overcome these therapeutic insufficiencies, the 
Japanese multicenter phase II study HERBIS-1 was ini-
tiated. HERBIS-1 recruited patients with advanced, 
HER2-positive gastric cancer. Patients received S1 on 
day 1–14, cisplatin on day one and trastuzumab on day 
one of a cycle of 21 days. The response rate, taken from 
the RECIST trial, was 68 % (95 % confidence interval (CI) 
0.54–0.80) and the disease control rate was 94 % (95 % CI 
0.84–0.99). The median OS, the PFS and the time to treat-
ment failure (TTF) were estimated at 16.0, 7.8, and 5.7 
month, respectively [31].
Upcoming trials to evaluate the value of trastuzumab 
in gastric cancer are ML25189, a phase II study, plan-
ning to recruit 45 patients suffering from resectable and 
HER2 positive gastric adenocarcinoma or gastro-esoph-
ageal junction cancer (type I–III) [32] and the US Radia-
tion Therapy Oncology Group (RTOG)-1010 accrues for 
a larger, phase III trial with a planned number of 480 
patients [33].
New approaches targeting HER2
The HER2-targeted monoclonal antibody pertuzumab 
inhibits HER2 heterodimerization. Binding the extracel-
surgery and a reduced tumor size were observed [23]. As 
a result of the MAGIC trial, perioperative chemotherapy 
was established as standard regimen in resectable gastric 
cancer in wide parts of Europe.
Implication of targeted therapy
Due to improvements in understanding altered molec-
ular events in cancer the discovery of new targets and 
agents in gastric cancer were possible. Targeted therapy 
for solid tumors represents a new therapeutic onset. 
Nevertheless, some notable successes could have been 
reached. In advanced or metastatic gastric cancer a cura-
tive therapeutic onset is exceedingly rare. Still, the focus 
in advanced stages is on palliation and best supportive 
care.
HER2
HER2, a 185-kDa protein, is encoded by a gene located on 
chromosome 17q21. Overexpression of HER2 in gastric 
cancer is reported in 6–23 % [7, 24]. Due to carcinogenic 
processes and adverse pathological features overexpres-
sion of HER2 is related to poor prognosis in gastric cancer 
[25, 26]. Besides its association with clinicopatholgical 
features, HER2 amplification is a promising target for tar-
geted therapy [27].
In gastric cancer, the expression of HER2 is primar-
ily determined by using immunohistochemistry (IHC) 
and/or by detecting HER2 gene amplification by in situ 
hybridization (ISH) as described previously by Hofmann 
et al. in 2008. Rüschoff et al. reassessed this method in 
2010 ([28, 29]; Fig. 1).
Trastuzumab in gastric cancer
Trastuzumab is the first molecular targeted agent 
approved as standard therapy in gastric cancer [8, 30]. 
Trastuzumab induces antibody dependent cellular cyto-
toxicity. In addition, trastuzumab inhibits HER2 medi-
ated signaling and prevents cleavage of the extracellular 
domain for HER2. An addition of trastuzumab to con-
Fig. 1 a Esophagogastroduo-
denoscopy showing a gastric 
adenocarcinoma in the fundus 
ventriculi. b Dual-color in situ 
hybridization: red centromere 
chromosome 17, black the 
HER-2 gene. Note that the 
ratio of HER-2 gene copies/
centromere 17 is < 2 in the 
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Angiogenesis in gastric cancer
Angiogenesis is a fundamental factor in tumor growth. 
Due to angiogenesis oxygen and nutrients are supplied 
to proliferating cancer cells [9]. Endothelial cell prolifer-
ation is controlled by VEGFR-2. Beside others, VEGFR-2 
is the most important signal transducer in angiogenesis 
and additionally, VEGFR-2 plays a major role in prolif-
eration, migration, permeability, invasion and tube for-
mation of endothelial cells [9, 45–48]. Thus, VEGFR-2 
provides a possible target using antiangiogenic drugs in 
the treatment of gastric cancer.
Sunitinib is an orally available, TKI of VEGFR-1, − 2, 
and − 3, platelet-derived growth factor receptors (PDGF-
R) α and β, KIT and other TKIs [49, 50]. In two phase II 
studies, using sunitinib in patients with advanced gastric 
cancer no benefit in survival could be observed. Besides 
that, patients in both studies suffered from severe adverse 
effects [51, 52]. Another randomized phase II trial com-
bined sunitinib with chemotherapy in pretreated patients 
with unresectable or metastatic gastric cancer. Likewise, 
in the two studies using sunitinib as monotherapy for 
advanced gastric cancer, no significant benefit in survival 
or time to progression could be observed [53].
Antiangiogenic agents in gastric cancer
Bevacizumab is a humanized monoclonal antibody 
blocking the binding of VEGF to its receptors. AVAGAST, 
a global, randomized, phase III trial, investigated che-
motherapy with capecitabine xeloda/cisplatin versus 
chemotherapy with capecitabine xeloda/cisplatin plus 
bevacizumab. Beside PFS and overall response rate (ORR) 
showed significant improvements, the primary endpoint 
median OS was not reached (HR = 0.87; p = 0.1002) [54]. 
The AVATAR study, a Chinese, randomized, phase III 
trial, using the same study design, found no significant 
improvement in survival as well [55].
Ramucirumab is a humanized immunoglobulin G1 
monoclonal antibody, showing promising antitumor 
effects in a number of malignancies [56]. The REGARD 
trial, a global, randomized, double-blind, phase III trial 
of 355 patients with progressive disease, investigated the 
addition of ramucirumab to standard chemotherapy. 
This addition brought a significantly prolonged median 
OS (3.8 to 5.2 month, p = 0.0473) [57].
The RAINBOW trial investigated ramucirumab as 
second-line treatment in patients with advanced gastric 
or gastro-esophageal junction cancer and disease pro-
gression after first-line chemotherapy, showing a signifi-
cantly better OS in the ramucirumab plus chemotherapy 
group (median 9.6 vs. 7.4 month, p = 0.017) [58]. Due to 
these results, the FDA has approved ramucirumab in 
April 2014.
lular domain II of the HER2 receptor, pertuzumab there-
fore disrupts HER2 dimerization not competing the effect 
of trastuzumab [34–36].
A phase IIa study of first-line pertuzumab showed only 
partial response. The combination with trastuzumab, 
capecitabine, and cisplatin in HER2 positive, advanced 
gastric cancer patients, brought no remarkable benefits 
[37].
Lapatinib, a TKI of EGFR and HER2 showed promising 
results in HER2 positive breast cancer previously. Until 
today, no significant benefit in gastric cancer could be 
observed using lapatinib in recently published studies 
[38].
Trastuzumab emtansine (trastuzumab-DM1), a con-
jugate of cytotoxic drug maitansine derivate DM1 and 
trastuzumab, binds microtubules and inhibits their 
assembly and blocks mitosis, likewise vinca alkaloids do. 
Using in vitro gastric cancer models, trastuzumab-DM1 
shows highly aggressive tumor activity compared with 
single trastuzumab [39]. Currently, a multicenter phase 
III study of trastuzumab-DM1 is recruiting patients with 
HER2-positive advanced gastric cancer after progression 
after first-line treatment [40].
Strategies to overcome trastuzumab-resistance
Beside improved outcome in patients with HER2 positive 
gastric cancer due to trastuzumab, the median duration 
of response remains moderate. A multitude of patients, 
suffering from HER2-positive gastric cancer develop 
secondary resistance to trastuzumab [38]. Thus, a bet-
ter understanding of the molecular mechanisms in the 
development of resistance to trastuzumab is urgently 
needed.
Afatinib is an irreversible inhibitor of EGFR, HER2, and 
HER4. Afatinib are potentially active against receptors 
with secondary mutations, resistant to first-generation 
inhibitors. A phase II study in metastatic HER2-positive 
trastuzumab refractory esophageal and gastric cancer is 
underway, currently recruiting patients [41].
The PI3K/Akt/mTOR pathway plays a cruitial role in 
trastuzumab resistance, dysregulating the HER2 down-
stream signal [42]. The mTOR inhibitor everolimus 
inhibits the mTOR/S6K signal, and therefore improves 
fluorouracil-induced apoptosis in gastric cancer cells 
with HER2 amplification. A concordant therapy using 
HER2-targeted agents and everolimus might lead to an 
improvement in therapy of HER2-positive gastric cancer.
HSP90, an ATP dependent, conserved molecular 
chaperone, plays a major role in the structural fold-
ing and stability of proteins. AUY922, a member of the 
isoxazole HSP90 inhibitor family, might be a promising 
agent to overcome secondary trastuzumab resistance 
[43]. Unfortunately, a clinical phase II study brought no 
results due to premature termination [44].
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Discussion
The role of targeted therapy in gastric cancer emerged 
over the last few years. HER2 status and angiogenesis, 
both associated with disease aggressiveness were recog-
nized and established as prognostic markers. As shown 
and described in this study, preclinical as well as clini-
cal trials have proved the importance of combining con-
ventional chemotherapy and targeted therapy in gastric 
cancer.
Until now, trastuzumab remains the only monoclo-
nal antibody showing significant benefits in gastric can-
cer. Due to the development of trastuzumab-resistance 
the positive effects are limited. Currently a number of 
promising molecules, showing synergistic effects in con-
comitant use with trastuzumab to overcome secondary 
resistance are under investigation. In the therapeutic 
field of angiogenic inhibitors, ramucirumab and apatinib, 
both VEGFR-2 inhibitors, remain the only two promising 
agents until now. As in HER2-directed targeted therapy, 
mechanisms for intrinsic or secondary resistance to anti-
angiogenic therapy need to be unmasked.
Combined targeting of HER2 and VEGF showed 
encouraging inhibition rates in breast cancer. Due to 
these findings, further studies and trials, combining 
HER2 and VEGF-targeted therapies in gastric cancer are 
necessary.
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